Evidence map›Paper›PMID 40956859›Full record

ArticlePLoS biology2025

Hexokinase 2 is an RNA-binding protein that regulates mRNA translation independently of glycolysis and induces melanoma cell proliferation.

Ana Luisa Dian, Lucilla Fabbri, Antoine Moya-Plana, Giuseppina Claps, Juliana C Ferreira, Céline M Labbé, Virginie Quidville, Sylvain Martineau, Dorothée Baille, Laetitia Besse and 7 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ana Luisa DianInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.
Lucilla FabbriInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.
Antoine Moya-PlanaINSERM U.981, Gustave Roussy, Villejuif, France.
Giuseppina ClapsINSERM U.981, Gustave Roussy, Villejuif, France.
Juliana C FerreiraScience Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Céline M LabbéInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.
Virginie QuidvilleINSERM U.981, Gustave Roussy, Villejuif, France.
Sylvain MartineauInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.
Dorothée BailleInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.
Laetitia BesseInstitut Curie, Université P.S.L., CNRS UAR2016, Inserm U.S.43, Université Paris-Saclay, Multimodal Imaging Center, Orsay, France.
Cédric MessaoudiInstitut Curie, Université P.S.L., CNRS UAR2016, Inserm U.S.43, Université Paris-Saclay, Multimodal Imaging Center, Orsay, France.
Séverine RoyINSERM U.981, Gustave Roussy, Villejuif, France.
Virginie RaynalInstitut Curie Genomics of Excellence (ICGex) Platform, PSL Research University, Institut Curie Research Center, Paris, France.
Sylvain BaulandeInstitut Curie Genomics of Excellence (ICGex) Platform, PSL Research University, Institut Curie Research Center, Paris, France.
Wael M RabehScience Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Caroline RobertINSERM U.981, Gustave Roussy, Villejuif, France.
Stéphan VagnerInstitut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France.ORCID 0000-0003-1452-7164

Funding

Agence Nationale de la Recherche (ANR)Centre National de la Recherche Scientifique (CNRS)Horizon Europe Marie Sklodowska-Curie Actions (MSCA)Institut National de la Santé et de la Recherche Médicale (Inserm)
6 · The paper itself

Abstract

Although metabolic benefits of glycolysis have been extensively described in tumor cells, the extra-metabolic functions linked to this energetic pathway in tumor growth and cell proliferation have not been clearly established yet. Recently, some key glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase 2, were reported to regulate mRNA translation. Translational control of gene expression is considered as a critical effector in cancer biology, representing a highly promising area of research. Here, we report that Hexokinase 2 (HK2), a glucose kinase that catalyzes the first step of glycolysis at the outer mitochondrial membrane (OMM), is an RNA-binding protein (RBP) that regulates mRNA translation in melanoma cell lines. Polysome profiling experiments followed by RNA sequencing indicate that the translational regulation exerted by HK2 is partly independent of the metabolic status or the glycolytic pathway. We found that HK2 specifically regulates translation of the mRNA encoding SOX10, a transcription factor implicated in the regulation of tumor initiation, maintenance, and progression in melanoma. RNA-protein interaction assays, including CrossLinking ImmunoPrecipitation (CLIP), indicate that HK2 is an RBP whose interaction with RNA is independent of its enzymatic activity, its ability to bind glucose or its association with the OMM. HK2 directly interacts with the 5' untranslated region (5'UTR) of the SOX10 mRNA through a stem-loop RNA secondary structure. Using RNA-protein proximity ligation assays and a fluorescence-based ribosome-bound mRNA mapping method, we found that high glucose conditions, which promote the release of HK2 from the OMM, induce an increase in HK2-SOX10 mRNA interaction and SOX10 mRNA translation in the cytoplasm. We further showed that HK2-dependent SOX10 mRNA translation is involved in melanoma cell proliferation and colony formation. Collectively, our data highlight a nonmetabolic function of HK2 acting as an RBP and translation regulator.

Indexed as

HexokinaseMelanomaProtein BiosynthesisRNA-Binding ProteinsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlycolysisHumansPolyribosomesRNA, MessengerHexokinaseHK2 protein, humanRNA-Binding ProteinsRNA, Messenger

Identifiers

PMID40956859
PMCPMC12494293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.